Search Results

AM-2394 25 mg  | 99.58%

TargetMol

AM-2394 is an effective and specific Glucokinase agonist (GKA, EC50: 60 nM), which catalyzes the phosphorylation of glucose to glucose-6-phosphate. AM-2394(AM2394) increases the affinity of GK for glucose by approximately 10-fold, exhibits moderate clearance and good oral bioavailability in multiple animal models, and lowers glucose excursion following an oral glucose tolerance test in an ob/ob […]

More Information Supplier Page

S107 2 mg  | 99.63%

TargetMol

S107 is a RyR-selective 1, 4-benzothiazepine derivative that stabilizes RyR2 channels by enhancing the binding affinity of calstabin2 to mutant and/or PKA-phosphorylated channels.

More Information Supplier Page

S107 25 mg  | 99.63%

TargetMol

S107 is a RyR-selective 1, 4-benzothiazepine derivative that stabilizes RyR2 channels by enhancing the binding affinity of calstabin2 to mutant and/or PKA-phosphorylated channels.

More Information Supplier Page

VU0155041 25 mg  | 100.00%

TargetMol

VU0155041 is an effective and positive allosteric modulator/allosteric agonist at mGlu4 receptors (EC50: 798/693 nM, at human/rat).

More Information Supplier Page

KS176 2 mg  | 99.55%

TargetMol

KS176 is a potent and selective inhibitor of the breast cancer resistance protein (BCRP) multidrug transporter, showing no inhibitory activity against P-gp or MRP1.

More Information Supplier Page

URB602 25 mg  | 99.64%

TargetMol

URB602 is a specific monoacylglycerol lipase (MGL) inhibitor, which inhibits rat brain MGL (IC50: 28±4 μM) through a noncompetitive mechanism.

More Information Supplier Page